Tikomed's ILB® attenuates clinical symptoms and serum biomarkers of oxidative/nitrosative stress and mitochondrial dysfunction in ALS patients, data published by the Journal of Personalized Medicine
Viken – 16[th] August 2021 – New study results for Tikomed’s platform lead drug candidate ILB[® ]in the treatment of patients with amyotrophic lateral sclerosis (ALS), have now been published in the Journal of Personalized Medicine. The data revealed a significant normalization of the serum levels of several key metabolites in addition to a significant improvement of patients’ clinical conditions for the duration of the ILB[®] treatment period. The treatment response appears to be mediated by improvement of tissue bioenergetics, decrease of oxidative/nitrosative stress and attenuation of (